

Faculty Disclosures

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, course directors, planners, moderators, faculty, and all others in control of the educational content of the continuing education activity must disclose all financial relationships with ineligible companies that they may have had within the past 24 months. If an individual refuses to disclose financial relationships, they will be disqualified from being a part of the planning and implementation of the activity. Owners and/or employees of an ineligible company with business lines or products relating to the content of the activity will not be permitted to participate in the planning or execution of any accredited program. All listed relevant financial relationships with ineligible companies for individuals in control of content have been mitigated.

Name	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
Naim Alkhouri, MD (Arizona Liver Health)	Speaker	<ul style="list-style-type: none"> • 89Bio, Boehringer Ingelheim Pharmaceuticals, Inc., Echosens, Fibronostics, Gilead Sciences, Inc., Intercept, Madrigal, NorthSea, Novo Nordisk, Perspectum, Pfizer, Inc., Zydus • AbbVie Inc., Alexion Pharmaceuticals, Inc., Echosens, Eisai, Gilead Sciences, Inc., Intercept, Ipsen, Perspectum, Theratechnologies • 89Bio; Akero; AstraZeneca; Better Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Corcept Therapeutics Inc.; DSM; Galectin; Genentech; Gilead Sciences, Inc.; Hepagene; Healio; Hepion; Intercept; Inventiva; Ionis; Ipsen; Madrigal; Merck; NGM; Noom; NorthSea; Novo Nordisk; Perspectum; Pfizer Inc.; Poxel; Viking; Zydus 	<ul style="list-style-type: none"> • Consultant, Advisory Board • Speakers Bureau • Research Funding
Jennifer Au, MD (Scripps)	Speaker	<ul style="list-style-type: none"> • Genentech 	<ul style="list-style-type: none"> • Consultant
Munveer Bhangoo, MD (Scripps)	Speaker	<ul style="list-style-type: none"> • Exelixis, Astellas, Pfizer 	<ul style="list-style-type: none"> • Speakers Bureau
Christopher Bowlus, MD (UC Davis)	Speaker	<ul style="list-style-type: none"> • Gilead, BMS, Cymabay Therapeutics, Genfit, GSK, Mirum, Pliant, Novartis, BiomX, Boston Scientific, Cour Pharmaceuticals, Target Pharmsolutions 	<ul style="list-style-type: none"> • Grant Funding
Kenneth Cusi, MD (University of Florida)	Speaker	<ul style="list-style-type: none"> • Janssen, Novartis, Novo Nordisk, Octeta • Deuterex, Janssen, Kowa, Lilly, Novartis, Novo Nordisk, Pfizer, Teva, Tobira, Zydus 	<ul style="list-style-type: none"> • Research Funding • Consultant
Adam Deising, MD (Scripps)	Speaker	<ul style="list-style-type: none"> • Salix, Mallinckrodt 	<ul style="list-style-type: none"> • Speaker

Name	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
Jordan Feld, MD (Toronto General Hospital)	Speaker	<ul style="list-style-type: none"> AbbVie, Antios, Arbutus, BluejayTherapeutics, Deep Genomics, Finch, Gilead, GSK, Janssen AbbVie, Alexion, Altimune, Eiger, Enanta, Gilead, GSK, Janssen, Wako/Fujifilm 	<ul style="list-style-type: none"> Consultant Research Funding
Jonathan Fisher, MD (Scripps)	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Pierre Gholam, MD (Case Western Reserve University)	Speaker	<ul style="list-style-type: none"> Bayer, Onyx, Otsuka, Vertex, AbbVie, Gilead, Merck AbbVie, Gilead, Merck 	<ul style="list-style-type: none"> Consulting Honoraria
Julio Gutierrez, MD (Scripps)	Course Co-Director	<ul style="list-style-type: none"> AbbVie, Altimune, Gilead, HepaTx, Intercept, Livivos, and Madrigal AbbVie, Alexion, Exilexis, Gilead, Intercept, and Madrigal Escient, Surrozen 	<ul style="list-style-type: none"> Consultant Speaker Data Safety Monitoring Board
Anita Kohli, MD (Arizona Liver Health)	Speaker	<ul style="list-style-type: none"> Gilead, Intercept, Novartis Intercept Lilly, Gilead, Inrrecept, Novartis, Regeneron 	<ul style="list-style-type: none"> Advisory Board Speakers Bureau Research Funding
Raymond Lee, MD (Scripps)	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Paul Pockros, MD (Scripps)	Course Director	<ul style="list-style-type: none"> Gilead, AbbVie, Intercept, Bayer, Mallinckrodt, Altimune, Boston Pharmaceuticals Intercept, Orphalan Intercept, ChemoMab Intercept 	<ul style="list-style-type: none"> CME Grants paid to SH and U Louisville Data Safety Monitoring Advisory Board Research Grants paid to Scripps Health Speaker
Sammy Saab, MD (UCLA)	Speaker	<ul style="list-style-type: none"> AbbVie, Eisai, Exelixis, Gilead, Intercept, Salix, Takeda, Mallinckrodt Gilead, Mallinckrodt, Eisai, Exelixis 	<ul style="list-style-type: none"> Speakers Bureau Consultant
Aditya Sarvaria, MD (Scripps)	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Claude Sirlin, MD (UCSD)	Speaker	<ul style="list-style-type: none"> GE Healthcare, GE MRI, GE US, Siemens, Gilead, ACR Innovation, Bayer, Philips Enanta, Gilead, ICON, Intercept, Nusirt, Shire, Synageva, Takeda AMRA, Fulcrum Therapeutics, IBM Watson Health AMRA, Guerbet, Bristol Myers Squibb 	<ul style="list-style-type: none"> Research Funding Lab Service Consultant Advisory Board
Norah Terrault, MD (Keck)	Speaker	<ul style="list-style-type: none"> Moderna Gilead, GSK, Roche-Genentech, Helio Health 	<ul style="list-style-type: none"> Data Safety Monitoring Board Research Funding
CME Committee	CE approval, all final decision-making on activities	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A

Name	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
Scripps Conference Services & CME	Plan, manage, implement, and reconcile CE activities	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A

Glossary of Terms

Ineligible Company

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit www.accme.org/standards.

Financial Relationships

Financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor, research funding, royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed.